Loading publications…
The last 5 uploaded publications
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. , 183, DOI: https://doi.org/10.1016/j.ejca.2023.01.016.
Article62 days agoPrognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma
Emanuel Buehrer, Nina Glassée, Michal Kiciński, Oliver John Kennedy, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma. , DOI: https://doi.org/10.1016/j.ejcskn.2025.100727.
Article62 days agoEfficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
Samuel Cass, Joshua W.D. Tobin, Yongwoo David Seo, Georgina Gener‐Ricos, Emily Z. Keung, Elizabeth M. Burton, Michael A. Davies, Jennifer L. McQuade, Alexander J. Lazar, Robert M. Mason, Michael Millward, Shahneen Sandhu, Chloe Khoo, Lydia Warburton, Veronica Guerra, Andrew Haydon, Helen Dearden, Alexander M. Menzies, Matteo S. Carlino, Jessica L. Smith, Peter Mollee, Melinda Burgess, Sally Mapp, Colm Keane, Victoria Atkinson, Sameer A. Parikh, Svetomir N. Markovic, Wei Ding, Timothy G. Call, Paul J. Hampel, Georgina V. Long, Jennifer A. Wargo, Alessandra Ferrajoli (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. , 34(9), DOI: https://doi.org/10.1016/j.annonc.2023.06.007.
Article62 days agoNeoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba2.
Article62 days agoQuality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
Minke W. Lucas, Reetta Arokoski, Alexander M. Menzies, Saskia Pulleman, Robyn P.M. Saw, Winan J. van Houdt, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Célèste Lebbé, Matteo S. Carlino, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse, Judith Lijnsvelt (2024). Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba9584.
Article62 days ago